Lipocine is a pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. The company's key product candidate, TLANDO?, is an oral testosterone replacement therapy. Additional pipeline candidates include LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of non-alcoholic steatohepatitis, LPCN 1111, an oral testosterone therapy product with the potential for once daily dosing, and LPCN 1107, which has the potential to become an oral hydroxyprogesterone caproate product indicated for the prevention of recurrent preterm birth.
Zacks Investment Research is a Chicago based firm with over 30 years of experience in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.